

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Drug Program®

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|--|-----------------------------------|----------------------------|--|----------------|-------------|-------------------|
| Alhemo® Inj 60/1.5ml, 150/1.5ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 01/27/25 |
| Alhemo® Inj 300/3ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 03/10/25 |
| Alyftrek™ Tab | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 01/06/25 |
| auranofin cap 3mg (Brand: Ridaura®) | NPD/SP* | No Change (New Generic) | | No Change | No Change | 02/24/25 |
| clobetasol cre 0.025% (Brand: Impoyz®) | NPD | No Change (New Generic) | 3 prescription strength, generic topical steroids | No Change | No Change | 03/10/25 |
| esomeprazole pow 2.5mg, 5mg (Brand: Nexium®) | G + PA + QL (1 packet per day) | No Change (New Generic) | | No Change | No Change | 01/13/25 |
| Esperoct® Inj 4000iu | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 02/03/25 |
| Evrysdi [®] Tab 5mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 02/24/25 |
| Fenopron™ Cap 300mg | NPD + PA | No Change (New Drug) | 3 generic prescription strength NSAIDS (e.g., ibuprofen, naproxen, diclofenac, celecoxib, meloxicam caps/tabs, etc.) | No Change | No Change | 01/20/25 |

(continued)

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

^{*=} for Specialty plans

^{** =} May be available as generic for certain plans

 $^{^{\}wedge}$ = Age Edits categories include all drugs that are affected by this change

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|--|---------------------------------------|---------------------------------------|---|----------------|-------------|-------------------|
| ferric citra tab 210mg (Brand: Auryxia®) | NPD | No Change (New Generic) | | No Change | No Change | 03/24/25 |
| Fulvicin™ P/G Tab 165mg | NPD + PA | No Change (New Drug) | Generic griseofulvin 125mg tablet, 250mg tablet, 500mg tablet | No Change | No Change | 02/03/25 |
| Gabarone® Tab 100mg, 400mg | NPD + PA | No Change (New Drug) | Generic gabapentin | No Change | No Change | 01/13/25 |
| Gomekli™ Cap 1mg, 2mg, 1mg Oral Suspension | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 02/24/25 |
| griseofulvin tab ultr 165 (Brand: Fulvicin™ P/G) | G + PA | No Change (New Generic) | Generic griseofulvin 125mg tablet, 250mg tablet, 500mg tablet | No Change | No Change | 02/10/25 |
| Imbruvica® Cap 140mg Oral | NPD/SP* + PA + QL (2 caps per day) | NPD/SP* + PA + QL (4 caps per day) | | No Change | QL Update | 10/01/25 |
| Inzirqo™ Sus 10mg/ml | NPD + PA | No Change (New Drug) | Oral solid dosage formulation (tablet or capsule) of the drug requested OR one of the following: drug will be administered via nasogastric or gastronomy tube; or member is unable to swallow an intact capsule or tablet | No Change | No Change | 03/17/25 |
| Isturisa® Tab 5mg | NPD/SP* + PA + QL (2 tabs per day) | NPD/SP* + PA + QL (6 tabs per day) | | No Change | QL Update | 10/01/25 |
| ivermectin tab 6mg | G | No Change (New Drug) | | No Change | No Change | 03/24/25 |

(continued)

^{*=} for Specialty plans

 $^{^{**}=}$ May be available as generic for certain plans

^{^ =} Age Edits categories include all drugs that are affected by this change

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|--|-----------------------------------|-----------------------------------|--|----------------|-------------|-------------------|
| Jivi® Inj 4000 unit | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 01/20/25 |
| Journavx™ Tab 50mg | NPD + QL (30 tabs per 14 days) | NPD + QL (30 tabs per 90 days) | | No Change | QL Update | 10/01/25 |
| lactulose pak 20gm (Brand: Kristalose®) | NPD + PA | No Change (New Generic) | lactulose solution | No Change | No Change | 02/17/25 |
| levetiraceta tab 250mg (Brand: Spritam®) | NPD + PA | No Change (New Generic) | generic levetiracetam | No Change | No Change | 01/27/25 |
| meman/donepz cap 14-10mg, 28-10mg (Brand: Namzaric®) | G | No Change (New Generic) | | No Change | No Change | 01/20/25 |
| meman/donepz cap 21-10mg (Brand: Namzaric®) | G | No Change (New Generic) | | No Change | No Change | 03/03/25 |
| mercaptopuri sus 20mg/ml (Brand: Purixan®) | G/SP* | No Change (New Generic) | | No Change | No Change | 03/10/25 |
| metaxalone tab 640mg | G + PA | No Change (New Drug) | 2 generic skeletal muscle relaxants (e.g., carisoprodol, tizanidine, cyclobenzaprine, chlorzoxazone 500mg, etc.) | No Change | No Change | 03/03/25 |
| metformin tab 750mg | LCG + PA | No Change (New Drug) | ONE of the following: metformin IR 500mg, 850mg, metformin 1000mg | No Change | No Change | 01/20/25 |
| 0mvoh™ Inj 100/200 | PB/SP* + PA | No Change (New Drug) | | No Change | No Change | 03/03/25 |
| Otulfi® Inj 45/0.5ml, 90mg/ml | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 03/10/25 |

^{*=} for Specialty plans (continued)

Please note: Prescription drug benefits vary by group. Therefore, a drug on this formulary does not imply coverage.

 $^{^{**}=}$ May be available as generic for certain plans

^{^ =} Age Edits categories include all drugs that are affected by this change

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|---|---|----------------------------|---|----------------|-------------|-------------------|
| Palforzia® Cap Level 0, 1-3yrs | NPD + PA | No Change (New Drug) | | No Change | No Change | 02/24/25 |
| Prevymis® Pak 20mg, 120mg | NPD/SP* | No Change (New Drug) | | No Change | No Change | 01/20/25 |
| prucalopride tab 1mg, 2mg | G + PA | G | | No Change | PA Removal | 10/01/25 |
| Raldesy™ Sol 10mg/ml | NPD + PA | No Change (New Drug) | 3 generic antidepressants (e.g., citalopram tablet, venlafaxine, bupropion, sertraline tablet, etc.) | No Change | No Change | 03/10/25 |
| Revuforj® Tab 25mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 03/24/25 |
| rivaroxaban tab 2.5mg (Brand: XareIto®) | G | No Change (New Generic) | | No Change | No Change | 03/10/25 |
| Rybelsus® Tab 1.5mg, 4mg, 9mg | PB + PA + QL (1 tab per day) | No Change (New Drug) | | No Change | No Change | 02/24/25 |
| sacub/valsar tab 24-26mg, 49-51mg, 97-103mg (Brand: Entresto®) | G + QL (2 tabs per day) | No Change (New Generic) | | No Change | No Change | 01/27/25 |
| Sevenfact® Sol 2mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 03/24/25 |
| Simlandi® Kit 20/0.2ml, 80/0.8ml | NPD/SP* + PA + QL (2 kits per 28 days) | No Change (New Drug) | | No Change | No Change | 02/03/25 |
| Simlandi® 1pn Kit 80/0.8ml | NPD/SP* + PA + QL (2 kits per 28 days) | No Change (New Drug) | | No Change | No Change | 03/24/25 |
| timolol hemi sol 0.5% op (Brand: Betimol®) | G | No Change (New Generic) | | No Change | No Change | 01/13/25 |

^{*=} for Specialty plans

(continued)

^{**} = May be available as generic for certain plans

^{^ =} Age Edits categories include all drugs that are affected by this change

| Drug Name | Current (tier and edit) | New Tier and Edit | Formulary Alternatives | Tier Change | Edit Change | Effective Date |
|------------------------------|----------------------------|-------------------------|---|----------------|-------------|-------------------|
| topiramate cap 50mg | G | No Change (New Drug) | | No Change | No Change | 01/20/25 |
| Tremfya® Croh Inj 200/2ml | PB/SP* + PA | No Change (New Drug) | | No Change | No Change | 03/31/25 |
| Tryngolza™ Inj 80mg/0.8 | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 010/6/25 |
| ustekinumab sol ttwe | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 03/31/25 |
| Xpovio® Pak 40mg | NPD/SP* + PA | No Change (New Drug) | | No Change | No Change | 03/17/25 |
| Xromi® Sol 100mg/ml | NPD + PA | No Change (New Drug) | Oral solid dosage formulation (tablet or capsule) of the drug requested OR one of the following: drug will be administered via nasogastric or gastronomy tube; or member is unable to swallow an intact capsule or tablet | No Change | No Change | 03/03/25 |
| Zunveyl® Tab 5mg, 15mg | NPD + PA | No Change (New Drug) | Minimum 30-day supply of two of the following: generic galantamine, generic rivastigmine, generic donepezil | No Change | No Change | 03/03/25 |
| Zunveyl® Tab 10mg | NPD + PA | No Change (New Drug) | Minimum 30-day supply of two of the following: generic galantamine, generic rivastigmine, generic donepezil | No Change | No Change | 03/10/25 |

^{*=} for Specialty plans

 $^{^{**}=}$ May be available as generic for certain plans

^{^ =} Age Edits categories include all drugs that are affected by this change

Abbreviation Key

| G | Generic |
|---|--|
| LCG | Low Cost Generic. Benefit may vary; not all plans provide this incentive. |
| ACA | Affordable Care Act preventative drugs |
| PB | Preferred Brand |
| NPD | Non-Preferred Drug |
| SP | Specialty Drug. Specialty Tier cost-share will apply for those benefits that have a prescription drug specialty tier. |
| PA | Prior Authorization is required. |
| MME | Morphine Milligram Equivalent |
| D/S | Days Supply Limit |
| QL | Quantity Limit |
| AL | Age Limit |
| Generic Addition | A generic drug that recently became available in the marketplace |
| Generic Downtier | This generic drug will be covered at the appropriate preferred drug level of cost-sharing. |
| Generic Uptier | This generic drug will be covered at the appropriate non-preferred drug level of cost-sharing. |
| Authorized Generic Addition | An authorized generic drug that recently became available in the marketplace |
| Authorized Generic Uptier | Authorized generics are brand drugs that are marketed without the brand name on its label. An authorized generic may be marketed by the brand name drug company, or another company with the brand company's permission. Unlike a standard generic drug, the authorized generic is not approved by the Food and Drug Administration (FDA) abbreviated new drug application process (ANDA). This authorized generic drug will be covered at a higher level of cost-sharing similar to other brand name drugs. |
| Brand Downtier | These brand drugs were added to the formulary as of the date indicated and are covered at the appropriate preferred brand formulary level of cost-sharing. |
| Brand Uptier | These brand drugs will be covered at the appropriate non-preferred drug level of cost-sharing. |
| Brand Addition | Coverage was added to this drug. |
| Brand/Authorized Generic/ Generic Deletion | Coverage was removed from this drug. Formulary alternatives are available. |